University of Utah Health researchers have shown that a protein involved in cancer growth also plays a role in whether a ...

From increasing price transparency to curbing prescription drug costs, states are trying to figure out how to rein in rising ...

The FDA has approved Mimrylo (rusfertide) to treat adults with polycythemia vera (PV), a blood cancer that causes the overproduction of red blood cells. The excess cells thicken t ...

In theory, agentic AI’s ability to self-refine could mean improved patient outcomes. Hennessy says it also raises questions for regulators and end users, because assessments of AI agents will quickly ...

Repatha (evolocumab) lowered the risk of death from any cause by 20% in high-risk adults without a previous heart attack or ...

The FDA has approved Lilly’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke in ...

Medicare Advantage enrollees who developed a new complex condition, such as congestive heart failure or Alzheimer’s disease, were more likely to leave their plan for traditional Medicare the next year ...

The FDA has approved Lisraya (brepocitinib) to treat adults with dermatomyositis, rare autoimmune disease. Dermatomyositis ...

Eli Lilly’s Zepbound real-world study shows older adults with obesity cut non-drug healthcare costs 25% via fewer hospital and ER visits, informing Medicare coverage.

Shifting focus, there's a lot going on in the individual market — in the ACA [Affordable Care Act] exchange plans — with the end of the enhanced tax credits. There's a flight to high-deductible bronze ...